Luke Saunders, None;
Alexa Li, None;
Akram Belghith, None;
Felipe Medeiros, Alcon Laboratories, Inc. (R), Alcon Laboratories, Inc. (C), Allergan, Inc. (F), Allergan, Inc. (C), Allergan, Inc. (R), Bausch & Lomb (F), Carl Zeiss Meditec, Inc. (F), Carl Zeiss Meditec, Inc. (R), Carl Zeiss Meditec, Inc. (C), Heidelberg Engineering, Inc. (F), Merck Inc. (F), National Eye Institute (F), Novartis (C), Reichert, Inc. (R), Reichert, Inc. (F), Sensimed (F), Topcon, Inc. (F);
Jeffrey Goldberg, None;
Jeffrey Liebmann, Allergan, Inc. (C), Allergan, Inc. (F), Bausch & Lomb, Inc. (F), Bausch & Lomb, Inc. (C), Carl Zeiss Meditech, Inc. (F), Diopysis, Inc. (C), Diopysis, Inc. (F), Heidelberg Engineering, GmbH (C), Heidelberg Engineering, GmbH (F), Merz Pharmaceuticals, Inc. (C), Optovue, Inc. (F), Quark Pharmaceuticals, Inc. (F), Reichert, Inc. (F), Sensimed, Inc. (F), Topcon, Inc. (F), Valeant Pharmaceuticals, Inc. (C);
Christopher Girkin, Carl Zeiss Meditec, Inc. (F), EyeSight Foundation of Alabama (F), Heidelberg Engineering, GmbH (F), National Eye Institute (F), Research to Prevent Blindness (F), SOLX (F);
Christopher Bowd, None;
Robert Weinreb, Aerie (F), Alcon (C), Allergan (C), Amatek (C), Aquesys (C), Bausch & Lomb (C), Carl Zeiss Meditec (F), Carl Zeiss Meditec (C), Genentech (F), Heidelberg Engineering GmbH (F), Nidek (F), Novartis (F), Optovue (F), Topcon (F), Topcon (C), Valeant (C);
Linda Zangwill, Carl Zeiss Meditec, Inc. (F), Carl Zeiss Meditec, Inc. (P), Heidelberg Engineering GmbH (F), Nidek, Inc. (F), Optovue, Inc. (F), Quark (F), Topcon Medical Systems, Inc. (F)